R&D Credit vs. Section 174: How They Work Together in Life Sciences
Life sciences companies, especially pre-revenue startups, are inordinately impacted by taxation. On the one hand, the R&D credit provides significant tax relief, covering up to 25% of qualified expenses; on the other hand, Section 174 requires some costs to be amortized over a period of years.
While recent updates to these laws eased the burden for domestic research activities, any foreign expenses must still be capitalized over 15 years.
In light of these facts, it would seem the two rules were at cross-purposes. However, they can work well together (and can actually help you preserve runway) if you understand how they interact and plan accordingly.
Let’s unpack.
Understanding the Federal R&D Tax Credit
The R&D credit is intended to fuel innovation. Following OBBB updates to Section 41, there is a significant incentive to conduct that research domestically.
The R&D credit does not reduce taxable income. Rather, it provides a dollar-for-dollar credit to offset research costs for various qualified expenses, including salaries, preclinical lab activities, trial design and execution, process development, formulation, testing, software development, data system development, cloud computing expenses (so long as they are tied to eligible development activities), process improvement, and contracted research costs, the latter of which may comprise up to 65% of eligible costs.
To be eligible for the credit, organizations must satisfy a federally mandated four-part test, the components of which are:
Permitted purpose (aka business component test), wherein the research is focused on creating or improving a business component, e.g., a process, product, formula, software, or a novel invention.
The activity must be technological in nature, meaning it relies on hard science such as biology, engineering, physics, or chemistry.
Elimination of uncertainty, which denotes that the activity must attempt to resolve uncertainty around the product’s design, methodology, or potential for development.
Process of experimentation, meaning the organization must be evaluating alternatives through modeling, simulation, or trial and error to eliminate technical uncertainty.
Taxpayers must satisfy all four criteria to qualify for the credit. If there is more than one business component, they must be treated as unique entities; in other words, each of the four standards must be applied separately to each business component.
Pre-revenue companies benefit from the credit, which can be applied to up to $500,000 in payroll taxes annually, providing meaningful cash flow at critical early stages.
And while the R&D credit is offered at the federal level, many states offer additional incentives and tax credits, increasing the value.
Deconstructing Section 174
Before 2022, Section 174 allowed research-focused companies to deduct eligible expenses in the year they were incurred.
With the enactment of the Tax Cuts and Jobs Act (TCJA), taxpayers were required to capitalize and amortize these same expenses over a period of years: five years for domestic research and 15 years for foreign research, with a mid-year convention.
This meant that taxpayers could deduct only a portion of their expenses and must amortize the rest over the appropriate period. The downshot of this is that it falsely inflated taxable income, a particular concern for pre-revenue companies.
Fortunately, this portion of the TCJA was amended for the 2025 tax year, restoring the ability to deduct R&D and R&E expenditures immediately. Companies may now elect to amend their returns for 2022-2024 under Section 174A.
However, the rule change only applies to domestic activities. Foreign research still requires a 15-year amortization. Companies that feel there is a benefit to continuing to amortize research may also elect to do so.
Section 174 vs. R&D Tax Credit: What’s the Difference?
Though both rules apply to research and development spending, they have unique purposes.
Under Section 41, the R&D tax credit provides a tax incentive to support innovation.
Section 174, on the other hand, relates to the timing of when those costs can be deducted.
And while there is significant overlap between the two schemes, Section 174 applies more generally to experimental and research activities, while Section 41 is more specific and limited.
What does this mean in practice?
Under Section 174, the taxpayer must capitalize and amortize costs over the required timeframe (5 years for domestic, 15 years for foreign).
At the same time, the taxpayer may also claim the R&D credit for eligible expenses.
Because deductions under 174 are deferred, taxable income increases. However, the R&D credit partially eases the impact by offsetting a portion of the company’s tax liability.
Proactive Tax Planning is Essential
With more stringent reporting and documentation requirements set to become law next year, proactive tax planning is a must.
Taxpayers in the pre-revenue phase should evaluate their eligibility for the payroll tax credit and ensure their documentation is in order.
For commercial and growth-phase companies, it is critical to understand how Section 174 might affect tax rates and payment estimates going forward.
Meticulous cost tracking is essential and should be properly categorized by business component. When reporting rules change next year, this will provide options and potentially a huge advantage at tax time.
Domestic and foreign research costs must be separated to ensure accurate projections. When considering expansion in this area, the impact of foreign activities should be factored into decisions.
Review contractor agreements through the lens of potential credits and their potential value.
Align finance, tax, and R&D teams to optimize efficiency.
Keep track of legislative changes to ensure your methods align with current tax law.
The Bottom Line: Align R&D Credits to Section 174 for the Win
R&D spending is a fact of life for life sciences companies. The federal government incentivizes innovation with substantial tax credits, but taxpayers must be mindful of the Section 174 timing rules.
When the two strategies are aligned, spending directly correlates to tax outcomes. While it’s a complex environment, it also introduces incredible opportunities. With the right planning, financial modeling, and processes in place, taxpayers can preserve runway and improve cash flow on their way to the next breakthrough.
Speak to a Growise expert today and learn how we support your mission.